Alliance for Clinical Trials in Oncology
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- 251
- Market Cap
- -
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Phase 3
Not yet recruiting
- Conditions
- Castration-Sensitive Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
- Interventions
- Drug: Androgen TherapyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Bone ScanProcedure: PSMA PET ScanProcedure: Biospecimen CollectionOther: Questionnaire Administration
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1260
- Registration Number
- NCT06931340
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Phase 3
Not yet recruiting
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Early Stage Breast Carcinoma
- Interventions
- Procedure: EchocardiographyProcedure: Multigated Acquisition ScanProcedure: MammographyProcedure: UltrasoundProcedure: Magnetic Resonance ImagingProcedure: Biospecimen CollectionOther: Questionnaire Administration
- First Posted Date
- 2025-03-14
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1524
- Registration Number
- NCT06876714
Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial
Phase 3
Recruiting
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage 1 Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast Carcinoma
- Interventions
- Procedure: MammogramProcedure: Magnetic Resonance ImagingBiological: Dual X-ray AbsorptiometryProcedure: Biospecimen CollectionOther: Questionnaire Administration
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1156
- Registration Number
- NCT06671912
- Locations
- 🇺🇸
Bon Secours Saint Mary's Hospital, Richmond, Virginia, United States
🇺🇸Keck Medicine of USC Buena Park, Buena Park, California, United States
🇺🇸Enloe Medical Center, Chico, California, United States
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Phase 3
Recruiting
- Conditions
- Clear Cell Renal Cell CarcinomaRenal Cell Carcinoma (RCC)Stage II Renal Pelvis Cancer AJCC v8Stage III Renal Pelvis Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionProcedure: MRIProcedure: Computed TomographyProcedure: BiopsyOther: Questionnaire Administration
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1040
- Registration Number
- NCT06661720
- Locations
- 🇺🇸
Beebe South Coastal Health Campus, Millville, Delaware, United States
🇺🇸Helen F Graham Cancer Center, Newark, Delaware, United States
🇺🇸Kootenai Clinic Cancer Services - Post Falls, Post Falls, Idaho, United States
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Phase 3
Recruiting
- Conditions
- Resectable Lung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8Stage IIIB Lung Cancer AJCC v8
- Interventions
- Procedure: Surgical ProcedureProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1100
- Registration Number
- NCT06632327
- Locations
- 🇺🇸
South Sacramento Cancer Center, Sacramento, California, United States
🇺🇸Kaiser Permanente-San Francisco, San Francisco, California, United States
🇺🇸Kaiser Permanente-Santa Teresa-San Jose, San Jose, California, United States
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Phase 2
Recruiting
- Conditions
- Castration-Resistant Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
- Interventions
- Other: Genetic testingProcedure: Magnetic Resonance ImagingProcedure: Computed TomographyProcedure: Bone scanProcedure: FDG-Positron Emission TomographyProcedure: PSMA PET ScanProcedure: Biospecimen Collection
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 474
- Registration Number
- NCT06632977
- Locations
- 🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸UC San Diego Health System - Encinitas, Encinitas, California, United States
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Phase 1
Not yet recruiting
- Conditions
- Recurrent Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- Procedure: EchocardiographyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyProcedure: Bone Marrow BiopsyProcedure: Bone Marrow AspirationProcedure: Biospecimen Collection
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 88
- Registration Number
- NCT06232044
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
🇺🇸OhioHealth O'Bleness Hospital, Athens, Ohio, United States
🇺🇸OhioHealth Marion General Hospital, Marion, Ohio, United States
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
Phase 2
Recruiting
- Conditions
- Pancreatic Acinar Cell CarcinomaPancreatic AdenocarcinomaPancreatic Adenosquamous CarcinomaPancreatic CarcinomaPancreatic Ductal AdenocarcinomaStage IV Pancreatic Cancer AJCC v8Pancreatic Squamous Cell Carcinoma
- Interventions
- Procedure: Magnetic Resonance ImagingProcedure: Computed TomographyProcedure: Biospecimen Collection
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 100
- Registration Number
- NCT06115499
- Locations
- 🇺🇸
Essentia Health-Hayward Clinic, Hayward, Wisconsin, United States
🇺🇸Essentia Health-Spooner Clinic, Spooner, Wisconsin, United States
🇺🇸Essentia Health Saint Mary's Hospital - Superior, Superior, Wisconsin, United States
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Phase 3
Recruiting
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Other: Patient ObservationProcedure: Bone Marrow BiopsyOther: Fludeoxyglucose F-18Procedure: Positron Emission TomographyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: ColonoscopyProcedure: EsophagogastroduodenoscopyProcedure: Biospecimen CollectionOther: Questionnaire Administration
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 421
- Registration Number
- NCT05976763
- Locations
- 🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸City of Hope at Irvine Lennar, Irvine, California, United States
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Phase 3
Recruiting
- Conditions
- Early Stage Triple-Negative Breast CarcinomaAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8
- Interventions
- Other: Patient ObservationProcedure: BiopsyProcedure: Biospecimen CollectionOther: Questionnaire AdministrationOther: Quality-of-Life Assessment
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1295
- Registration Number
- NCT05812807
- Locations
- 🇺🇸
Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States
🇺🇸UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States
🇺🇸Advocate Christ Medical Center, Oak Lawn, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath